Rouba Kozak

Company: Foundation for the National Institute of Health

Job title: Director of Mental Health, Translational Sciences

Seminars:

Transforming the Translational Validity of Preclinical Psychosis Models: Moving Beyond Dopamine-Focused Assays to Study New Anti-Psychosis Drug Mechanisms & Demonstrate Clinically Relevant Readouts 9:00 am

Current psychosis research often uses pharmacological models targeting dopamine but fails to capture the disorder's complexity. These models lack translational accuracy and overlook biological diversity among patients. Emerging research emphasizes the importance of integrative models that include glutamatergic, GABAergic, inflammatory, and neurodevelopmental mechanisms. There's increasing demand for validated biomarkers reflecting diverse mechanisms to improve patient…Read more

day: Pre-Conference Day

Investor Panel: Navigating Partnerships, & Investment Challenges in Psychosis Drug Development 3:00 pm

Explore the scientific, regulatory, and commercial uncertainties that make psychosis R&D a uniquely high-risk category, and how these risks shape both pharma and investor interest Discuss how innovative startups and emerging biotech companies can forge mutually beneficial relationships with pharma and venture investors What makes a small biotech compelling? Insights into what large pharma and…Read more

day: Day Two